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Objectives: Eliciting preferences and trade-offs that
patients may make to achieve important outcomes, can
assist in developing patient-centred research and care.
The pilot study aimed to test the feasibility of a case 2
best–worst scaling survey (BWS) to elicit recipient with
kidney transplantation preferences after transplantation.
Design: Preferences for graft survival and dying,
cancer, cardiovascular disease, diabetes, infection and
side effects (gastrointestinal, weight-gain and
appearance) were assessed in recipients with
transplantation using a BWS (20 scenarios of nine
outcomes). Participants chose ‘best’ and ‘worst’
outcomes. Responses were analysed using a
multinomial logit model. Selected participants were
interviewed.
Outcomes: Attribute coefficients and survey
completion error rates.
Results: 81 recipients with transplantation were
approached, and 39 (48%), mean age 50.5 years,
completed the BWS. 4 (10%) surveys were invalid with
major errors and of 35 remaining, 7 of 1400 (0.5%)
choices were missing. –23 (59%) took >20 min to
complete the survey. 1 was unable to finish, and 1 did
not understand the survey. 2 (5%) found it very hard
and 14 (35%) moderately hard. Most attribute
coefficients were significant (p<0.05) and showed face
validity. Graft survival was most important with
normalised coefficients from 1 (95% CI 0.89 to 1.11)
to 0.06 (95% CI −0.03 to 0.16) for 30 and 1 year
duration, respectively. Attribute level coefficients
decreased with increasing risk of adverse outcomes.
Error rates of 20% and 2% were estimated for
dominant attributes ‘100% risk of dying’ and ‘30 years
graft survival’, respectively. 7 participants were
interviewed regarding counterintuitive selection of
‘100% risk of dying’ as a ‘best’ outcome.
Misunderstanding, not linking dying to graft survival
and aversion to dialysis were reasons given.
Conclusions: Recipients with transplant recipients
successfully completed a complex case 2 BWS with
attribute coefficients having face validity with respect to
duration of graft survival and risk of adverse outcomes.
Areas for refinement to reduce complexity in design
have been identified.
INTRODUCTION
Compared with dialysis, kidney transplant-
ation offers improved survival and quality of
life in most patients with end-stage kidney
disease, but lifelong immunosuppression is
required to maintain graft function.
Immunosuppression is not without harms
and may lead to bacterial/fungal or viral
infections, post-transplant diabetes mellitus
and malignancy.1–3 Prior research has quanti-
fied the frequency and severity of adverse
effects associated with long-term immuno-
suppression,4–7 and there is a body of evi-
dence showing that recipients with kidney
transplantation have a strong focus on graft
survival, an aversion to returning to dialysis,
and a willingness to accept side effects and
adverse outcomes as being a necessary part
of the treatment.8–12 However, no studies
have quantified the trade-offs that patients
may be willing to make to reduce the impact
of debilitating side effects or adverse events
such as cancer through minimisation or with-
drawal of immunosuppression and the risk of
graft dysfunction. To date, as with many
chronic diseases, treatment decisions have
been predominantly driven by clinicians with
Strengths and limitations of this study
▪ Ability to elicit preferences and trade-offs for
multiple outcomes of varying severity in a way
that minimises cognitive burden and error rates.
▪ Survey design that reflects the complexity of
treatment outcomes after kidney transplantation.
▪ Interviews of selected participants to explore
reasons for counterintuitive responses.
▪ Bias to English speaking recipients with trans-
plantation and with a higher level of education.
▪ The importance of graft survival may be overesti-
mated due to use of 30 years graft survival in
the best–worst scaling survey.
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little patient involvement,13–17 thus, understanding
patient preferences and trade-offs is key to facilitating
communication and shared decisions.
Understanding patient preferences and values are
important to effective communication and facilitating
informed and shared decisions that recognise the vari-
ation in tolerance of risk.18–20 While preferences reflect
an individual’s tastes (likes or dislikes) and ideals (per-
sonal values and commitments), they will also reflect
their reference point (such as having experienced dialy-
sis or not), psychological traits (imaginative capacity,
optimism, inertia), social influences (norms and laws,
influence of family and friends) and beliefs (under-
standing of the likelihood and consequences of an
outcome).21 22 In the context of a complex and long-
term treatment that involves trade-off between poten-
tially debilitating side effects and adverse outcomes of
immunosuppression and graft dysfunction, clinicians
can have a substantial influence on patient preferences
through the content and style of communication.18
Understanding the extent to which patient preferences
are underpinned by personal beliefs and how they vary
with factors such as age, gender, and previous and
current health states, provides a basis for identifying
potentially erroneous beliefs11 23 and the development
of communication strategies best suited to facilitate con-
struction of preferences that align with the transplant
recipient’s own values.24 25
The aim of this pilot study was to evaluate the feasibil-
ity of best–worst scaling (BWS), a type of discrete choice
experiment,26 to elicit preferences, priorities and trade-
offs between outcomes following transplantation of
patients with kidney transplants. By contrast with conven-
tional discrete choice experiments, some authors have
suggested that BWS offers a number of potential advan-
tages relevant to the assessment of complex treatment
outcomes27 including statistical efficiency,28 29 the ability
to estimate attribute-level coefficients on a common
scale allowing for direct comparison both between and
within attributes, and may also be less cognitively
demanding than conventional discrete choice or
ranking experiments.30 For these reasons, there has
been growing interest in the use of BWS surveys in
health-related research.27 However, the application of
BWS surveys to complex treatment regimens, such as




Adult patients with kidney transplants (aged ≥18 years)
attending a single transplant centre in Sydney, Australia,
were eligible to participate. Respondents could complete
the survey while attending the outpatient clinic, by
phone or by email. The survey was in English, and
non-English speaking patients were excluded.
BWS methodology
Best–worst attribute scaling, or ‘Case 2’ BWS26 27 meth-
odology was used. A ‘Case 2’ BWS requires participants
to choose the best and worst attribute from a single mul-
tiattribute profile.26 Preferences for attributes are
inferred from the choices made within the multiattri-
bute profiles rather than from choices made between
multiattribute profiles as is the case for traditional dis-
crete choice experiments. Unlike discrete choice experi-
ments, a BWS provides estimates of attribute-level
coefficients on a common scale allowing direct compari-
son of attribute levels within and between attributes.
Utility functions are constructed and estimated in
accordance with random utility theory as for discrete
choice experiments, however, with a BWS, the utility
functions are constructed for individual attributes rather
than for profiles.27
On the basis of the findings of an earlier qualitative
study,10 attributes considered most likely to be of import-
ance to patients with kidney transplants were included.
To minimise complexity, nine attributes were presented;
dying with a functioning graft, malignancy, cardiovascu-
lar disease, diabetes, infection, excessive weight gain,
gastrointestinal side effects, changes to appearance and
graft survival. A clinically realistic range of probabilities
was provided for the nine outcomes.1–3 31 The options
for graft survival were expressed in years. The attributes
and attribute levels are shown in table 1.
Survey design and administration
A d-efficient survey design was generated with parameter
values chosen to reflect expected direction of patient pref-
erence.32 The survey consisted of 20 multiattribute pro-
files, and was presented on paper or an online form.
Attribute levels that were expressed as risk of occurrence
were represented by words and numbers, and through
using pictograms to express the probability. Graft survival
was presented descriptively and graphically using a hori-
zontal bar graph showing years of graft survival (figure 1).
At the end of the survey respondents were asked whether
they ignored any attributes, how long it took to complete
the survey and how hard they found the survey to com-
plete. An open text box inviting any comments was
included at the end of the survey. The survey also included
questions on demographic and relevant medical details
including medication, number of transplants and the time
since last transplant. A paper version of the BWS was
either handed out or mailed, or a link was emailed to the
online version for those who agreed to complete the
survey. The surveys were self-completed without assistance
from researchers.
Analysis
All completed surveys were included for analysis with the
exception of those containing major errors where it was
not possible to identify the best and/or the worst selection.
Attribute-specific constants and attribute-level coefficients
were estimated using a multinomial logit (MNL) model
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with NLOGIT V.5.0 software (http://www.limdep.com).
For the purpose of the choice analysis, it was assumed that
the ‘best’ and ‘worst’ choices were selected sequentially,
with the ‘best’ selected first, and that attribute then not
available to be selected for the ‘worst’ choice. This assumes
that all nine attributes were available for the ‘best’ choice,
and that the ‘worst’ choice was made from only eight attri-
butes. The attribute-specific constant for ‘risk of change in
appearance’ and the attribute-level coefficient for ‘a 100%
risk of change in appearance’ were normalised to 0. The
attribute-specific constants thus represent the average of
the unobserved effects for the attributes relative to ‘appear-
ance’.29 The variables were coded such that a ‘best’ choice
for an attribute level was assigned a value of 1, a worst
choice a value of −1 and a value of 0 assigned when the
attribute level was not selected either as a ‘best’ or a ‘worst’.
Attribute-level coefficients were estimated from the com-
bined data set of the ‘best’ and the ‘worst’ choices, and
assumes that a best choice mirrors a worst choice, and that
there are no positive or negative framing effects.29 As the
attribute-level coefficients have the same underlying scale,
the coefficients have been normalised to a range 0–1 based
on the highest and lowest values from the MNL model. A
value of 0 means that attribute level was least preferred and
a value of 1 most preferred. All coefficients are expressed
as an average with a 95% CI.
Respondent interviews
As an additional check of the validity of the BWS attri-
butes and results, a subsample of respondents (n=7)
were interviewed by phone to assess the understanding
of concepts presented in the pilot survey. The questions
focused on the meaning of the attribute of dying with a
functioning graft. Individuals were selected on the basis
of choices where responses appeared to be counter
intuitive, for example, those who choose a very high risk
of dying as being the best attribute were interviewed.
Interviews were recorded and transcribed.
RESULTS
Participant characteristics
A total of 81 patients agreed to complete the BWS and
39 (48%) completed surveys were returned (figure 2).
The respondents, who were aged between 19 and
70 years (mean 50.5, SD 9.7), were predominantly men
(66%) and spoke English as a first language (87%), with
a majority (69%) having completed education beyond
high school. The time since the last transplant ranged
from 0.2 to 21.7 years (median 4.7) with 44% having
received grafts from deceased donors. Twenty-eight
(72%) of the respondents were currently taking tacroli-
mus and 35 (90%) prednisone. A summary of respond-
ent characteristics is presented in table 2.
Figure 1 Example of a single scenario from the best–worst
scaling survey.
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Supplementary questions
A summary of responses to the supplementary questions
is provided in figure 3. The majority of the respondents
(n=23 (59%)) reported that they took more than 20 min
to complete the survey (figure 3). One respondent was
unable to finish the questionnaire, and one respondent
reported that they did not understand the survey, while
2 (5%) and 14 (35%) found it very hard, or moderately
hard, respectively.
Twenty-three respondents (59%) stated that they
ignored one or more outcomes when completing the
BWS. The most frequently ignored outcomes were
‘gaining a large amount of weight’ and ‘change to your
appearance’ both of which were ignored by 16 (40%) of
the respondents, followed by ‘severe diarrhoea and
nausea’ which was ignored by 7 (18%). All other out-
comes (risk of cancer, cardiovascular disease (CVD),
serious infection, death and graft survival) were ignored
by 3 (8%) or fewer respondents (figure 3).
BWS analysis
Of the 39 surveys returned, 35 (90%) provided valid
data while the remaining four had major errors (missing
or multiple choices for either best and/or worst) affect-
ing all 20 scenarios and were excluded from further ana-
lysis (figure 2). Of the valid surveys, 7 of the 1400
(0.5%) choices were either invalid (more than one
choice entered) or missing, and were entered as missing
data giving a total of 1393 choices. Attribute-specific con-
stants and attribute-level coefficients are summarised in
table 3. The attribute-specific constants for ‘death’ and
‘graft survival’ were both significant (p<0.001) and posi-
tive which suggests that, all else being equal, respon-
dents were more likely to choose these attributes as
either a best or worst outcome. All other attribute-
specific constants were not significant (p>0.05).
Attribute coefficients were statistically significant
(p<0.05) for 30 (69%) of the 44 attribute levels with the
highest (most preferred) value of 4.58 (95% CI 3.79 to
5.38) being for graft survival of 30 years, and the lowest
(least preferred) value of −2.61 (95% CI −3.32 to
−1.89) for a 50% risk of cancer following transplant-
ation. The normalised (0–1) attribute level coefficients
are plotted in figure 4. The overall preference for an
attribute is indicated by the value of the attribute-level
coefficient with 1 being most preferred and 0 being least
preferred. The range of the coefficients for a specific
attribute provides an indication of the relative contribu-
tion that the attribute is likely to make to the overall
‘value’ or utility of a given scenario, with the wider
range indicating a greater contribution. For example,
graft survival has the greatest range with an upper value
of 1 (95% CI 0.89 to 1.11) for 30 years, and a lower
value of 0.06 (95% CI −0.03 to 0.16). All other attributes
have coefficient values and upper 95% confidence limits
<1. The attribute-level coefficients for graft survival
decreased with decreasing years of survival, and all
attribute-level coefficients were significantly different
from each other on the basis of the 95% CIs (figure 4).
A 50% chance of cancer, a 50% chance of CVD, and a
Figure 2 Flow of patients in
best–worst scaling survey. A valid
survey was one in which single
‘best’ and ‘worst’ choices were
clearly indicated by the
participant. A valid survey may
include individual scenarios that
were not completed, or with an
error making the selection
unclear, and thus have fewer than
the 20 valid scenarios available
for analysis.
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100% chance of debilitating gastrointestinal side effects
were not significantly >0 with 95% confidence limits all
<0, and they thus have an equivalent preference to
1 year of graft survival (ie, least preferred). The attribute
least likely to contribute to overall utility (ie, the one
with the narrowest range of attribute-level coefficients) is
the risk of side effects that change appearance with an
upper value of 0.62 (95% CI 0.45 to 0.79) and lower
value of 0.45 (95% CI 0.34 to 0.57) for a 0% and 75%
chance of occurrence after transplantation, respectively,
none of which were significantly different from each on
the basis of the 95% confidence limits.
Within each attribute, the coefficients for the attribute
levels generally moved in line with a priori expectations
(figure 4). A higher risk of harm, and lower graft sur-
vival were less preferred to lower risk of harms, or
higher graft survival. The only exception is ‘dying before
the kidney transplant fails’ where the point values for
the attribute-level coefficients show a ‘U’-shaped trend
(figure 4). A 0% chance of dying, had an attribute-level
coefficient of 0.65 (95% CI 0.54 to 0.77), and was
greater than all other risk levels, however, attribute-level
coefficients were not significantly different from each
other for a 25%, 50%, 75% or 100% chance of dying
with overlapping 95% CIs. This atypical trend in
attribute-level coefficients for the risk of dying may
reflect an indifference to an increasing risk of dying for
probabilities <25%, a rational choice made by some
respondents, or the result of misinterpretation of the
intended meaning of the attribute.
A 100% risk of dying, and 30 year graft survival, are
dominant attribute levels, and a choice of ‘best’ for
100% risk of dying would be ‘irrational’, and a choice of
‘worst’ for 30 years graft survival would be ‘irrational’.
The frequency of ‘irrational’ choices provides an indica-
tion of error associated with these dominant attributes.
A 100% risk of dying was available for selection as a
‘best’ or a ‘worst’ choice for 138 cases and was selected
as a ‘best’ choice in 28 cases (20%), which is indicative
of a high error rate. By contrast, 30 years graft survival
was selected as a ‘worst’ choice in 2 (2%) of 138 cases,
and suggests a relatively low rate of error particularly
compared to a 100% chance of dying. Reasons for the
high error rate associated with the risk of dying were
explored further through the interviews with selected
respondents.
Participant interviews
Seven participants were purposively selected for inter-
view based on their selection of a high risk of dying as a
‘best’ choice. The three reasons for the selection are:
Misunderstanding meaning: The meaning of the attribute
was interpreted differently to the intended definition.
For example, the response to a question as to what was
meant by 100 of 100 people will die was: ‘To me that
just means that the kidney will last a hell of a long time
or will outlast you’.
Not linking the risk of dying with the length of graft survival:
The risk of dying was considered in isolation from graft
survival rather than meaning a high risk of dying
before the graft fails, which in the case of 1 year graft
Table 2 Characteristics of participants






















Full time 24 (62)
Part time 2 (5)
Retired 6 (15)
Student 1 (3)
Not able to work 6 (15)
Highest education
University 14 (36)
Technical college 13 (33)
High school 11 (28)
Primary school 1 (3)
Number of transplants
1 only 32 (82)
Donor organ type
Deceased 17 (44)
Living related 18 (46)




Time since transplant (years)












Mycophenolate mofetil 25 (64)
Sirolimus 7 (18)
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survival would mean a short life span. For example:
‘Why I said 75 out of 100 people will die before their
kidney fails? Well as long as you don’t take the ques-
tions above [the kidney could last 1 year] into
account’.
Aversion to returning to dialysis: Dying with a functioning
graft was a better option than returning to dialysis even
if graft survival was relatively short for example: ‘…and
dying from other reasons rather than having to go on
dialysis wait for another one etc’.
DISCUSSION
This pilot study identified several key findings in relation
to the use of a BWS to elicit the preferences and prior-
ities of patients with kidney transplants for outcomes fol-
lowing transplantation. First, even with a relatively small
sample size, the majority of the attribute-level coeffi-
cients were statistically significant (p<0.05), and demon-
strate face validity with respect to relative importance
both within and between attributes. Graft survival of
30 years is more important than any other outcome and
a low risk of serious adverse outcomes is also highly pre-
ferred. A low risk (0%) of serious infection, cancer and
CVD has the same level of importance as approximately
20 years of graft survival. A very high risk (100%) of
severe gastrointestinal side effects has the same relative
importance as a high risk (50%) of cancer and CVD,
and short graft survival of 1 year. By contrast, a high risk
(100%) of changes to appearance is of low importance
relative to all other attributes. Similarly, the range of the
attribute-level coefficients indicate that graft survival is
likely to have the greatest contribution to assessment of
overall utility of the outcomes after transplantation, with
changes to appearance the smallest contribution.
Second, the pilot study had a low rate of major error
despite the use of a self-complete paper-based format
for a complex survey with 20 ‘best’/‘worst’ choice scen-
arios each containing nine attributes. Of the surveys
returned, 10% were unusable, and of the valid surveys
only 0.5% of the individual ‘best’ or ‘worst’ selections
were invalid. However, the estimated error rate for the
attribute of ‘dying before the transplanted kidney fails’
(as indicated by the rate of ‘irrational’ choice, assuming
that a high risk of dying would be ‘rationally’ identified
as an undesirable outcome) was in the order of 20%
compared with 2% for graft survival. The interviews with
respondents suggest that this error reflected misunder-
standing of the meaning of the attribute and a tendency
to view the risk of dying in isolation of the years of graft
survival. Nonetheless, it may be a ‘rational’ choice for
some individuals reflecting a stated preference for dying
over returning to dialysis.10
Third, with the exception of the risk of dying, the
attribute-level coefficients for adverse outcomes are
highest (most preferred) for low risk of occurrence, and
lowest (least preferred) for high risk of occurrence of
the outcomes. Similarly, attribute-level coefficients for
graft survival, are lowest (least preferred) for 1 year graft
survival, and increase with increasing years with the
maximum value (most preferred) at 30 years. In the case
of the risk of dying, the trend for decreasing preferences
Figure 3 Summary of responses to supplementary questions included in the best–worst scaling survey.
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with increasing risk is less apparent. As noted by de
Bekker-Grob et al,33 while most discrete choice evalua-
tions in health assume linearity in both attributes and
attribute coefficients, there are substantive reasons for
this to not be the case, and that non-linearity should be
taken into account when estimating trade-offs between
attributes.
LIMITATIONS
A number of observations from the pilot study warrant
consideration in ongoing studies of this type. While the
overall response rate for the study was close to 50%, it
differed by method of approach: following contact in
the clinic and by phone it was <30% compared to email
contact which had a 65% response rate. The character-
istics of the respondents were, in terms of gender and
age, generally representative of the kidney transplant
population, however, the sample is biased towards those
with higher levels of education, who were white and who
had English as a first language. These factors may have
influenced the low error rate found in the returned
surveys. The patient sample had a restricted range of
immunosuppressive agents which may limit representa-
tiveness in relation to variation in experience of side
effects, for example, 90% of the respondents were
taking prednisone and 72% tacrolimus. However, the
immunosuppression is characteristic of current clinical
practice in Australia and New Zealand.34
The upper range of graft survival at 30 years was close
to being a dominant attribute with almost all respondents
selecting this as the best outcome when it was included in
a choice scenario. This may overemphasise the relative
importance of graft survival particularly given the low
clinical probability of achieving 30 years. By contrast, the
relative importance of the ‘risk of dying with a function-
ing graft’ may be underestimated because of participant
misinterpretation and the subsequent error rate.
The analysis assumed symmetry of the ‘best’ and
‘worst’ choices, and that they come from the same
underlying utility function. This follows from the
approach of using a BWS as a data augmentation tech-
nique allowing for smaller sample sizes and less complex
experimental designs. This assumption of symmetry may
not be the case, and the ‘best’/‘worst’ choice may be
influenced by positive and negative framing.28 29
Furthermore, the analysis assumes that the ‘best’ and
‘worst’ choices are made sequentially as ‘best’ then
‘worst’ for all scenarios, whereas, it may be the other way
around, that is, ‘worst’ then ‘best’ for all or for some
scenarios, or the choice may be made simultaneously.28
The assumption of symmetry of choice and sequential
selection may result in biased estimates of the attribute-
level coefficients.
IMPLICATIONS FOR FUTURE RESEARCH
The findings of the pilot BWS have implications for
future research of patient preferences. The face validity
Table 3 Attribute specific constants and attribute level
coefficients from a multinominal logit model of the best–worst
scaling survey




Appearance Ref Ref Ref Ref
Weight −0.04 −0.49 0.41 0.848
Gastro −0.31 −0.81 0.20 0.234
Diabetes −0.39 −0.89 0.11 0.124
Death 1.59 1.23 1.94 0.000
Cardiovascular
disease
−0.14 −0.61 0.33 0.548
Cancer 0.06 −0.39 0.51 0.796
Infection −0.49 −1.16 0.17 0.146
Graft 1.47 1.09 1.84 0.000
Attribute level coefficients
Appearance 0 1.87 0.65 3.09 0.003
25 1.43 0.56 2.30 0.001
50 1.33 0.53 2.12 0.001
75 0.64 −0.17 1.46 0.122
100 Ref Ref Ref Ref
Weight 0 1.57 0.51 2.62 0.004
25 1.49 0.70 2.27 0.000
50 0.26 −0.51 1.03 0.508
75 −0.67 −1.47 0.13 0.100
100 −1.39 −2.09 −0.69 0.000
Gastro 0 2.45 1.36 3.54 0.000
25 0.44 −0.41 1.29 0.313
50 −0.88 −1.73 −0.03 0.041
75 −1.65 −2.49 −0.81 0.000
100 −2.42 −3.14 −1.70 0.000
Diabetes 0 2.30 1.14 3.46 0.000
10 1.13 0.18 2.08 0.020
20 0.66 −0.14 1.46 0.105
30 0.32 −0.52 1.16 0.453
50 −1.27 −2.07 −0.46 0.002
Death 0 2.10 1.31 2.90 0.000
25 0.28 −0.31 0.87 0.356
50 −0.95 −1.58 −0.32 0.003
75 −0.52 −1.17 0.12 0.108
100 0.22 −0.38 0.81 0.472
Cardiovascular
disease
0 3.00 2.08 3.96 0.000
10 0.71 −0.07 1.50 0.075
20 0.00 −0.80 0.78 0.987
30 −1.57 −2.42 −0.73 0.000
50 −2.40 −3.12 −1.70 0.000
Cancer 0 3.12 2.31 3.94 0.000
10 0.98 0.24 1.72 0.010
20 0.20 −0.54 0.95 0.595
30 −0.99 −1.80 −0.17 0.018
50 −2.61 −3.32 −1.89 0.000
Infection 0 3.36 2.38 4.34 0.000
10 1.97 1.07 2.88 0.000
20 2.14 1.26 3.01 0.000
30 0.71 −0.19 1.61 0.124
50 −1.56 −2.44 −0.68 0.001
Graft 30 4.58 3.79 5.38 0.000
20 2.47 1.81 3.13 0.000
10 1.11 0.52 1.71 0.000
5 −0.43 −1.05 0.19 0.178
1 −2.16 −2.83 −1.48 0.000
*All attribute levels are the risk of occurrence of the outcome
expressed as a percentage with the exception of graft which is
expressed as years of graft survival.
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and the low major error rate indicate that a BWS is a
feasible approach for eliciting preferences for long-
term outcomes associated with complex treatment regi-
mens and should also be applicable to conditions
other than immunosuppression after transplantation.
The types of situations suited to a BWS would be most
applicable where treatment regimens cannot easily be
described by discrete choices. In the case of recipients
of kidney transplants, treatment after transplantation is
more a process of adjusting the level and type of
immunosuppression to balance benefits (graft survival)
against harms (side effects and serious adverse out-
comes), rather than a choice between clearly distinct
treatment options. Describing treatment outcomes as
multiattribute single scenarios with differing attribute
levels, as in a BWS, is more realistic than the choice
scenarios of a discrete choice experiment. The pilot
study has shown that the conduct and analysis of a
BWS for complex treatment regimens should carefully
consider the meaning and understanding of outcomes,
and this may require participant interviews or a ‘think
out loud’ approach.35 Finally, the complexity of the
survey may limit participation and result in selection
bias. Future studies should explore survey administra-
tion techniques aimed at increasing accessibility and
response rates.
Specific to the ranking of importance of outcomes after
kidney transplantation, the findings of the pilot study can
be used to provide for more efficient designs by use of
better informed priors, and development of design
formats that minimise error resulting from cognitive
burden. For example, the use of a ‘best’ ‘worst’ ‘next best’
next worst’ format to reduce the number of scenarios.
CONCLUSIONS
The pilot study has indicated that patients with kidney
transplants were able to complete a complex BWS of pre-
ferences for multiple long-term outcomes after transplant-
ation and are willing to trade-off benefits and adverse
outcomes. The pilot survey identified some key findings
with respect to preferences and priorities recipients with
kidney transplantation that have implications for patient-
centred research. In particular, while graft survival is the
most important outcome, the pilot study suggests that a low
risk of serious adverse outcomes including potentially
debilitating side effects, such as severe diarrhoea and
nausea, may be of similar importance. This pilot has also
helped us identify refinements needed before administra-
tion in a larger patient sample, which is now being
undertaken.
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